PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850308.96349.64 |
| _version_ | 1827335099837841408 |
|---|---|
| author | J. P. Sharman W. Jurczak C. C. Coombs M. Hill D. Wang N. C. Ku A. Guntur S. Shahda C. C. Leow P. Ghia A. R. Mato |
| author_facet | J. P. Sharman W. Jurczak C. C. Coombs M. Hill D. Wang N. C. Ku A. Guntur S. Shahda C. C. Leow P. Ghia A. R. Mato |
| author_sort | J. P. Sharman |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:46Z |
| format | Article |
| id | doaj.art-91444f121bbd4639bd2470bd70b535f8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:46Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-91444f121bbd4639bd2470bd70b535f82024-03-02T07:47:30ZengWileyHemaSphere2572-92412022-06-0161744174510.1097/01.HS9.0000850308.96349.64202206003-01744PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)J. P. Sharman0W. Jurczak1C. C. Coombs2M. Hill3D. Wang4N. C. Ku5A. Guntur6S. Shahda7C. C. Leow8P. Ghia9A. R. Mato101 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, United States of America2 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland3 University of North Carolina at Chapel Hill, Chapel Hill4 Loxo Oncology at Lilly, Stamford, United States of America4 Loxo Oncology at Lilly, Stamford, United States of America4 Loxo Oncology at Lilly, Stamford, United States of America4 Loxo Oncology at Lilly, Stamford, United States of America4 Loxo Oncology at Lilly, Stamford, United States of America4 Loxo Oncology at Lilly, Stamford, United States of America5 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy6 Memorial Sloan Kettering Cancer Center, New York, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000850308.96349.64 |
| spellingShingle | J. P. Sharman W. Jurczak C. C. Coombs M. Hill D. Wang N. C. Ku A. Guntur S. Shahda C. C. Leow P. Ghia A. R. Mato PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) HemaSphere |
| title | PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_full | PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_fullStr | PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_full_unstemmed | PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_short | PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) |
| title_sort | pb1864 bruin cll 321 a phase 3 open label randomized study of pirtobrutinib vs investigator s choice of idelalisib rituximab or bendamustine rituximab in btki pretreated cll sll trial in progress |
| url | http://journals.lww.com/10.1097/01.HS9.0000850308.96349.64 |
| work_keys_str_mv | AT jpsharman pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT wjurczak pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT cccoombs pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT mhill pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT dwang pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT ncku pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT aguntur pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT sshahda pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT ccleow pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT pghia pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress AT armato pb1864bruincll321aphase3openlabelrandomizedstudyofpirtobrutinibvsinvestigatorschoiceofidelalisibrituximaborbendamustinerituximabinbtkipretreatedcllslltrialinprogress |